Founded in 2019, the company develops mRNA, self-replicating RNA, and delivery platforms. In 2026 it reported early JCXH-213 results in two patients with ITP; these findings should be distinguished from formal registered-trial phases and independent validation.
Research Triangle Park, North Carolina, USA; Hangzhou / Shanghai, ChinaOffice location disclosed on the corporate website; a sole legal or global headquarters is not inferred. ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Founded in 2019, the company develops mRNA, self-replicating RNA, and delivery platforms and discloses multiple clinical programs, including JCXH-211 and JCXH-105.
On 2026-06-29 the company reported early human results for its in vivo mRNA CAR-T candidate JCXH-213 in two patients with ITP. This small company-reported series does not establish efficacy in the broader population.
Immorna reports clinical investigation of JCXH-213, an RNA-based in vivo CAR-T candidate, in autoimmune diseases including ITP and systemic sclerosis. These are company-reported early findings, not proof of comparative efficacy; separate vaccine stages do not establish this program’s stage.
Program / service
Target / indication
Representative stage
Evidence & scope
JCXH-213
B-cell depletion (see the original source for the target) · Exploratory treatment of ITP and other autoimmune diseases
Early human results (company disclosure)
Company-reported results in two patients with ITP, without a control group or long-term follow-up
RNA / delivery technology platform
Project-dependent / not verified · Project-dependent / not verified
Clinical development (see sources for named programs)
This record does not establish human validation of the entire platform
JCXH-213
See program source; distinguish indications
Exploratory human study / IIT
Human research disclosed or registered; efficacy is not established.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
Azalea reported SITC preclinical findings for its dual-vector in vivo CAR-T platform, combining targeted CRISPR-Cas9 delivery with AAV-mediated CAR insertion at the TRAC locus. The company described leukemia clearance and protection after tumor rechallenge in selected mouse groups, plus dual-antigen and armored designs. These are animal findings, not evidence of efficacy or safety in patients.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
